Macquarie Group
AKCA

Macquarie Group’s Akcea Therapeutics Inc AKCA Stock Holding History

Macquarie Group’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,800
Closed -$31K – 2480
2017
Q4 		$31K Buy
+1,800
New +$35.3K ﹤0.01% 2151

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macquarie Group's AKCA Position: Q1 2018 in Review

Macquarie Group sold out of Akcea Therapeutics Inc (AKCA) in Q1 2018, closing a stake of 1,800 shares — an estimated $31K sold.

Macquarie Group first reported a position in AKCA in Q4 2017 and held it in 1 quarter. The position peaked at $31K in Q4 2017. 57 funds tracked by Wall St. Rank hold AKCA as of Q1 2018.

  • Macquarie Group reported no remaining Akcea Therapeutics Inc position as of Q1 2018 after selling out during the quarter.
  • Macquarie Group sold 1,800 Akcea Therapeutics Inc shares in Q1 2018, an estimated $31K.
  • Macquarie Group first reported a position in Akcea Therapeutics Inc in Q4 2017 and held it in 1 quarter.
  • Macquarie Group's Akcea Therapeutics Inc position peaked at $31K in Q4 2017.
  • 57 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.